{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Diseases&page=32", "query": { "condition": "Multiple Diseases", "page": 32 }, "page_size": 10 }, "pagination": { "page": 32, "page_size": 10, "total_count": 12232, "total_pages": 1224, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Diseases&page=33&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Diseases&page=31&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T18:55:07.568Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07348640", "title": "Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Steno-occlusive Disease" ], "interventions": [ { "name": "gadopiclenol", "type": "DRUG" }, { "name": "Gadoterate meglumine (Dotarem)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Guerbet", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 315, "start_date": "2026-07-28", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-11-11T18:55:07.568Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07348640" }, { "nct_id": "NCT02206425", "title": "Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Melphalan", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Ascorbic acid", "type": "DIETARY_SUPPLEMENT" }, { "name": "PLD", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2014-09", "completion_date": "2018-03-06", "has_results": false, "last_update_posted_date": "2023-10-31", "last_synced_at": "2026-11-11T18:55:07.568Z", "location_count": 12, "location_summary": "Bakersfield, California • Concord, California • Encinitas, California + 9 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02206425" }, { "nct_id": "NCT00693433", "title": "Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory Multiple Myeloma", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage III Multiple Myeloma" ], "interventions": [ { "name": "dexamethasone", "type": "DRUG" }, { "name": "temsirolimus", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2008-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-12-04", "last_synced_at": "2026-11-11T18:55:07.568Z", "location_count": 1, "location_summary": "Las Angeles, California", "locations": [ { "city": "Las Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00693433" }, { "nct_id": "NCT00087958", "title": "Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "XRP9881", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 168, "start_date": "2004-08", "completion_date": "2009-04", "has_results": false, "last_update_posted_date": "2009-05-01", "last_synced_at": "2026-11-11T18:55:07.568Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00087958" }, { "nct_id": "NCT06663358", "title": "A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Fabry Disease" ], "interventions": [ { "name": "Pegunigalsidase-alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Chiesi Farmaceutici S.p.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2024-11-06", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-11-11T18:55:07.568Z", "location_count": 6, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 3 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06663358" }, { "nct_id": "NCT01565655", "title": "A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "peficitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 289, "start_date": "2012-06-19", "completion_date": "2013-12-02", "has_results": false, "last_update_posted_date": "2025-05-21", "last_synced_at": "2026-11-11T18:55:07.568Z", "location_count": 19, "location_summary": "Birmingham, Alabama • La Jolla, California • Palm Desert, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Palm Desert", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Maria", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01565655" }, { "nct_id": "NCT02555215", "title": "Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "dimethyl fumarate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "10 Years to 17 Years" }, "enrollment_count": 20, "start_date": "2016-02-22", "completion_date": "2018-09-24", "has_results": true, "last_update_posted_date": "2019-11-22", "last_synced_at": "2026-11-11T18:55:07.568Z", "location_count": 1, "location_summary": "Loma Linda, California", "locations": [ { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02555215" }, { "nct_id": "NCT01951638", "title": "Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "Vericiguat (BAY1021189) (1.25 mg)", "type": "DRUG" }, { "name": "Vericiguat (BAY1021189) (5 mg)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 477, "start_date": "2013-11-06", "completion_date": "2015-09-16", "has_results": true, "last_update_posted_date": "2021-03-16", "last_synced_at": "2026-11-11T18:55:07.568Z", "location_count": 17, "location_summary": "Fountain Valley, California • Fort Lauderdale, Florida • Naples, Florida + 14 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Naples", "state": "Florida" }, { "city": "Macon", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01951638" }, { "nct_id": "NCT03041038", "title": "The Efficacy and Safety of Secukinumab in Patients With Ichthyoses", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ichthyosis", "Autosomal Recessive Congenital Ichthyosis", "Lamellar Ichthyosis", "Congenital Ichthyosiform Erythroderma", "Epidermolytic Ichthyosis", "Netherton Syndrome" ], "interventions": [ { "name": "Secukinumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2016-12", "completion_date": "2020-08-31", "has_results": true, "last_update_posted_date": "2021-08-25", "last_synced_at": "2026-11-11T18:55:07.568Z", "location_count": 2, "location_summary": "Chicago, Illinois • New York, New York", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03041038" }, { "nct_id": "NCT07284758", "title": "A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma", "Relapsed/Refractory Multiple Myeloma" ], "interventions": [ { "name": "Cemsidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "C4 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2026-02-18", "completion_date": "2030-03", "has_results": false, "last_update_posted_date": "2026-10-30", "last_synced_at": "2026-11-11T18:55:07.568Z", "location_count": 25, "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 19 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "West Hollywood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07284758" } ] }